Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for ...

Efficacy and safety of darolutamide in Chinese patients with metastatic hormone-sensitive prostate cancer (mHSPC): A subpopulation analysis of the phase 3 ARASENS study. This is an ASCO Meeting ...

For patients who have chronic lymphocytic leukemia (CLL), experiencing Richter transformation with central nervous system ...

-- Iomab-B led bone marrow transplant produced high rates of complete remission and durable complete remission regardless of TP53 mutation status in patients age 55 and above with high-risk active ...

Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for therapeutics. Among them, the Y220C mutation is the ninth most frequent and it ...

Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow transplant compared to 1.66 months in patients that did not receive ...

Adequate CD19-positive cell content is required to reliably identify both dominant and subclonal TP53 mutations. DNA was isolated in parallel from 2 different sample types from this patient: ...

A new single-cell profiling technique has mapped pre-malignant gene mutations and their effects in solid tissues for the ...